An orally active small molecule TGF-β receptor I antagonist inhibits the growth of metastatic murine breast cancer

Anticancer Research

Volumn 29, Issue 6, 2009, Pages 2099-2109

  Rausch, Matthew P ^a   Hahn, Tobias ^b   Ramanathapuram, Lalitha ^a   Bradley Dunlop, Deborah ^a   Mahadevan, Daruka ^c   Mercado Pimentel, Melania E ^d   Runyan, Raymond B ^d   Besselsen, David G ^e   Zhang, Xiamei ^f   Cheung, H Kam ^f   Lee, Wen Cherng ^f   Ling, Leona E ^f   Akporiaye, Emmanuel T ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f BIOGEN   (United States)

Author keywords

4T1; Breast cancer; SM16; Small molecule TGF RI ALK5 kinase inhibitor; TGF

Indexed keywords

GAMMA INTERFERON; PHOSPHOTRANSFERASE INHIBITOR; SM 16; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CELL CULTURE; CANCER INHIBITION; CELL INVASION; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; IN VITRO STUDY; MORPHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPLEEN CELL;

ADMINISTRATION, ORAL; ANIMALS; APOPTOSIS; AZABICYCLO COMPOUNDS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, NUDE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67650860451     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Pinkas J and Teicher BA: TGF-β in cancer and as a therapeutic target. Biochem Pharmacol 72: 523-529, 2006.
2. Kobie JJ and Akporiaye ET: Immunosuppressive rote of transforming growth factor beta in breast cancer. Clin Applied Immun Rev 3: 277-287, 2003. (Pubitemid 36612141)
3. Dennler S, Goumans MJ and ten Dijke P: Transforming growth factor beta signal transduction. J Leukoc Biol 71: 731-740, 2002.
4. Massague J: TGF-beta signal transduction. Annu Rev Biochem 67: 753-791, 1998.
5. Benson JR: Role of transforming growth factor beta in breast carcinogenesis. Lancet Oncol J: 229-239, 2004. (Pubitemid 38391218)
6. Akhurst RJ and Derynck R: TGF-beta signaling in cancer-a double-edged sword. Trends Cell Biol 11: S44-S51, 2001. (Pubitemid 33001443)
7. Krasagakis K, Tholke D, Farthmann B, Eberle J, Mansmann U and Orfanos CE: Elevated plasma levels of transforming growth factor (TGF)-beta 1 and TGF-beta 2 in patients with disseminated malignant melanoma. Br J Cancer 77: 1492-1494, 1998. (Pubitemid 28190751)
8. Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, Robecchi A, Emanuelli G and Rodeck U: Tumor associated transforming Growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 155: 537-547, 1999. (Pubitemid 29370403)
9. Shim KS, Kim KH, Han WS and Park EB: Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. Cancer 85: 554-561, 1999. (Pubitemid 29075277)
10. Wick W, Naumann U and Weller M: Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. Curr Pharm Des 12: 341-349, 2006.
11. Kong FM, Anscher MS, Murase T, Abbott BD, Iglehart JD and Jirtle RL: Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 222: 155-162, 1995.
12. Gorsch SM, Memoli VA, Stukel TA, Gold LI and Arrick BA: Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 52: 6949-6952, 1992. (Pubitemid 23006305)
13. Walker RA and Dearing SJ: Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer 28: 641-644, 1992.
14. Dumont N and Arteaga CL: Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta. Breast Cancer Res 2: 125-132, 2000. (Pubitemid 32223575)
15. Derynck R, Akhurst RJ and Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129, 2001. (Pubitemid 32952643)
16. McEarchern JA, Kobie JJ, Mack V, Wu RS, Meade-Tollin L, Arteaga CL, Dumont N, Besselsen D, Seftor E, Hendrix MJ, Katsanis E and Akporiaye ET: Invasion and metastasis of a mammary tumor involves TGF-beta signaling. Int J Cancer 91: 76-82, 2001.
17. Kobie JJ, Wu RS, Kurt RA, Lou S, Adelman MK, Whitesell LJ, Ramanathapuram LV, Arteaga CL and Akporiaye ET: Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 63: 1860-1864, 2003. (Pubitemid 36460849)
18. Yingling JM, Blanchard KL and Sawyer JS: Development of TGF-beta signaling inhibitors for cancer therapy. Nat Rev Drug Discov 3: 1011-1022, 2004. (Pubitemid 39642364)
19. Singh J, Ling LE, Sawyer JS, Lee WC, Zhang F and Yingling JM: Transforming the TFGβ pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TβRI (ALK5). Curr Opin Drug Discov Devel 7:437-445, 2004. (Pubitemid 44383550)
20. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS and Weller M: SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64: 7954-7961, 2004. (Pubitemid 39446929)
21. Ge R, Rajeev V, Ray P, Lattime E, Rittling S, Medicherla S, Protter A, Murphy A, Chakravarty J, Dugar S, Schreiner G, Barnard N and Reiss M: Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin Cancer Res 12: 4315-4330, 2006.
22. Ling LE, Chuaqui C, Boriack-Sjodin PA, Lepage D, Silverio E, Corbley MJ, Sun L, Papadatos J, Shan F, Pontz T, Cheung H-K, Zhang X, Arduini R, Mead J, Newman M, Bowes S, Josiah S, Lee WC and Singh J: The use of virtual screening in ALK5 kinase inhibitor discovery and validation of orally active ALK5 kinase inhibitors in oncology. In: Transforming Growth Factor-beta in Cancer Therapy, volume II cancer treatment and therapy. S. Jakowlew (ed.). Totowa, Humana Press Inc. 2008.
23. Fu K, Corbley MJ, Sun L, Friedman JE, Shan F, Papadatos JL, Costa D, Lutterodt F, Sweigard H, Bowes S, Choi M, Boriack-Sjodin PA, Arduini RM, Sun D, Newman MN, Zhang X, Mead JN, Chuaqui CE, Cheung HK, Zhang X, Cornebise M, Carter MB, Josiah S, Singh J, Lee WC, Gill A and Ling LE: SM16, An orally active TGF-β type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler Thromb Vasc Biol 28: 665-671, 2008.
24. Suzuki E, Kim S, Cheung HK, Corbley MJ, Zhang X, Sun L, Shan F, Singh J, Lee WC, Albelda SM and Ling LE: A novel small-molecule inhibitor of transforming growth factor β type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 67: 2351-2359, 2007.
25. Dexter DL, Kowalski HM, Blazar BA, Fligiel Z, Vogel R and Heppner G: Heterogeneity of tumor cells derived from a single mouse mammary tumor. Cancer Res 38: 3174-3181, 1978. (Pubitemid 9031291)
26. Wexler H: Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst 36: 641-645, 1966.
27. Kurt RA, Park JA, Panelli MC, Schluter SF, Marchalonis JJ, Carolus B and Akporiaye ET: T Lymphocytes infiltrating sites of tumor rejection and progression display identical V beta usage but different cytotoxic activities. J Immunol 154: 3969-3974, 1995.
28. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, Annunziata N and Doetschman T: Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359: 693-699, 1992.
29. Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, Story BM, Cornell JE, Pollock BH, Mundy GR and Sun LZ: Inhibition of pulmonary and skeletal metastasis by a transfonning growth factor-beta type I receptor kinase inhibitor. Cancer Res 66: 6714-6721, 2006. (Pubitemid 44085629)
30. Ananth S, Knebelmann B, Grüning W, Dhanabal M, Walz G, Stillman IE and Sukhatme VP: Transforming growth factor β1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 59: 2210-2216, 1999. (Pubitemid 29217687)
31. Bandyopadhyay A, Zhu Y, Malik SN, Kreisberg J, Brattain MG, Sprague EA, Luo J, López-Casillas F and Sun LZ: Extracellular domain of TGF-β type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene 21: 3541-3551, 2002. (Pubitemid 34587686)
32. Bandyopadhyay A, Wang L, Lopez-Casillas F, Mendoza V, Yeh IT and Sun L: Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. Prostate 63: 81-90, 2005. (Pubitemid 40365392)
33. Zhang F, Lee J, Lu S, Pettaway CA and Dong Z: Blockade of transforming growth factor-β signaling suppresses progression of androgen-independent human prostate cancer in nude mice. Clin Cancer Res 11: 4512-4520, 2005. (Pubitemid 40825642)
34. Gorelik L and Flavell R: Abrogation of TGF-β signaling in T-cells leads to spontaneous T-cell differentiation and autoimmune disease. Immunity 12: 171-181, 2000. (Pubitemid 30398631)
35. Gorelik L and Flavell R: Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T-cells. Nature Med 7: 1118-1122, 2001. (Pubitemid 33010019)